A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies
Clinical Trial Grant
Awarded By
ArQule, Inc.
Start Date
June 25, 2019
End Date
August 31, 2024
Awarded By
ArQule, Inc.
Start Date
June 25, 2019
End Date
August 31, 2024